Abstract
Background:
There is no high-quality, evidence-based protocol for the treatment of postoperative fatigue syndrome (POFS) after total joint arthroplasty (TJA) or fracture surgery with Chinese herbal medicine (CHM).
Purpose:
The purpose of this study was to explore the efficacy of CHM in the treatment of POFS after TJA or hip fracture surgery (HFS).
Methods:
We searched six databases to obtain randomized controlled trials (RCTs) of CHM for the treatment of POFS after TJA or HFS. The retrieval time limit was from the establishment of each database to August, 2022. According to the Cochrane Handbook for Systematic Reviews version 5.1, we used RevMan 5.3 to evaluate the quality of the studies. Stata 14.0 software was used to merge and analyze the data. The weighted mean difference (WMD) was the effect estimate for statistical analysis. We also performed subgroup analyses according to different types of surgeries.
Results:
A total of 11 RCTs were included in this study, comprising 430 cases in the CHM group and 432 cases in the control group (CG). The meta-analysis results showed that there was no significant difference in the Brief Profile of Mood States (BPOMS) score (WMD=0.08, 95% confidence interval (CI): -0.29 to 0.45, P=0.688), Christensen Fatigue scale (CHFS) score (WMD = 0.15, 95% CI: -0.09 to 0.39, P=0.214) or Identity-Consequence Fatigue Scale (ICFS) score (WMD=-0.40, 95% CI: -1.84 to 1.05, P=0.589) between the CHM group and the CG on the first postoperative day. The use of CHM significantly reduced the BPOMS score (WMD=-0.85 and WMD=-3.01, respectively), CHFS score (WMD=-1.01 and WMD= -1.45, respectively), and ICFS score (WMD=-3.51 and WMD=-5.26) on postoperative days 3 and 7. Compared with the CG, the CHM group had significantly increased serum transferrin and IgG levels on postoperative days 3 and 7. The subgroup analysis results suggested that the application of CHM in HFS patients improved fatigue symptoms on postoperative days 3 and 7, while the application of CHM to treat POFS in TJA patients had great inconsistency in the evaluation of different indicators.
Conclusion:
The application of CHM improved the fatigue status of POFS patients after TJA or HFS and increased the levels of transferrin and IgG in serum, which is conducive to promoting the postoperative rehabilitation process of patients. The subgroup analysis results showed that the application of CHM to intervene in POFS in HFS patients had obvious benefits.
Keywords: Chinese herbal medicine, postoperative fatigue syndrome, total joint arthroplasty, hip fracture surgery
1. INTRODUCTION
Postoperative fatigue syndrome (POFS) refers to a clinical syndrome in which patients have a series of symptoms, such as fatigue, depression, anxiety, insomnia, stress and inattention, after surgery, which seriously impair the quality of life and postoperative rehabilitation process of patients [1, 2]. POFS is a common complication after major surgery, which not only increases the inpatient burden of patients but is also not conducive to their recovery [3]. With aging, the prevalence of osteoarthritis, especially knee osteoarthritis and hip arthritis, continues to rise, which is associated with a heavy economic burden on the medical and health systems, patients, and society [4, 5]. Total joint arthroplasty (TJA), especially total hip arthroplasty (THA) and total knee arthroplasty (TKA), is the main treatment for end-stage bone and joint diseases [6, 7]. In particular, rehabilitation treatment after TJA or fracture surgery plays a key role in improving patients' postoperative satisfaction, improving quality of life and accelerating rehabilitation, and the occurrence of POFS undoubtedly hinders this process. Therefore, it is of great clinical value to explore an effective treatment for POFS after TJA or fracture surgery.
Notably, academic research on POFS started relatively late, and there is still a lack of research on POFS, especially on orthopedic surgery-related POFS. The pathogenesis and therapeutic targets of POFS are still unclear. At present, symptomatic treatment is the main treatment, and the therapeutic methods are limited. In recent years, Chinese herbal medicine (CHM), which can be applied in the form of decoctions, single herbal medicines, granules, capsules, etc., has been gradually used to treat PFOS. Miao et al. [8] showed that an herbal formula, Danggui Buxue decoction, can improve the fatigue symptoms of rats with fatigue syndrome, and its mechanism may be through interfering with the metabolism of ammonia, serine, and threonine. The effective components of single herbs, such as ginsenoside Rb1, have also been proven to improve the symptoms of fatigue in rats through the PI3K/Akt/Nrf2 signaling pathway [9]. According to this traditional Chinese medicine theory, CHM has a good clinical effect in the treatment of fatigue syndrome [10-12].
In recent years, the promotion and application of the concept of rapid rehabilitation have also indirectly encouraged bone surgeons to give importance to POFS. CHM is also used to treat POFS symptoms in patients after TJA or fracture surgery. However, there is no high-quality, evidence-based protocol for the treatment of POFS after TJA or fracture surgery with CHM; thus, surgeons and rehabilitation doctors may not be confident in employing this traditional herbal therapy. Therefore, we used a data synthesis method (meta-analysis) to provide an evidence-based evaluation of the efficacy and clinical application of CHM in the treatment of POFS after TJA or hip fracture surgery (HFS).
2. MATERIALS AND METHODS
The reporting of the implementation process and results of this study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [13].
2.1. Inclusion and Exclusion Criteria
The inclusion criteria followed the population, intervention, comparison, outcomes, and study (PICOS) principle. 1) The study subjects were patients diagnosed with POFS after TJA (such as THA or TKA) or HFS. 2) The intervention measures in the treatment group were CHM but only Chinese herbal formulas and proprietary Chinese medicines. 3) The control group (CG) received routine treatment after the operation, such as anti-infective, anticoagulant, or analgesic drugs and rehabilitation exercises. 4) Outcome measures included primary outcome measures (Christensen Fatigue scale (CHFS), Brief Profile of Mood States (BPOMS), and Identity-Consequence Fatigue Scale (ICFS) scores) [14-16] and secondary outcome measures (transferrin (TRF), IgG, and Visual Analog Fatigue Scale (VAS-F) scores). 5) The study design was a randomized controlled trial (RCT). 6) The diagnostic criteria of POFS were clearly stated in the included studies.
The exclusion criteria were as follows: 1) duplicate publication of the same research data, 2) incomplete data, and 3) the study did not report at least one of the outcome indicators we were investigating.
2.2. Retrieval Strategy
We searched the Cochrane Library, PubMed/Medline, and EMBASE databases, the Chinese Biomedical Literature Database (CBM), and the China National Knowledge Infrastructure (CNKI) and Wanfang databases. The retrieval time was from the establishment of each database to August, 2022. The keywords of the search form constructed in this study were Chinese herbal medicine, medicinal plants, phytochemicals, total joint arthroplasty, total knee arthroplasty, total hip arthroplasty, fatigue syndrome, and fatigue. The retrieval was carried out by combining subject words with free words and was adjusted according to the characteristics of each database. In addition, we traced the references of the included studies to obtain more studies that met the inclusion criteria. The search formula for each database is shown in Annex 1.
2.3. Literature Screening and Data Extraction
Two evaluators independently screened the studies, extracted the data, and assessed the methodological quality according to the inclusion and exclusion criteria of this study. Any differences were resolved through discussion or consultation with the corresponding authors. Two evaluators independently extracted data from the final included studies. The extracted data included author, title, year of publication, sample size, type of surgery, intervention measures, study quality evaluation information, outcome indicators, and outcome measurement data.
2.4. Study Quality Evaluation
Methodological quality was evaluated using the risk of bias assessment tool in the Cochrane Handbook for Systematic Reviews version 5.1. The evaluation contents included the generation of random sequences, allocation concealment, selective reporting, blinding, data loss, and other types of bias. According to the standards of the evaluation manual, the study was examined as having a low risk, high risk, or unclear risk of bias.
2.5. Data Analysis
We employed the statistical software RevMan 5.3 provided by the international collaborative network of evidence-based medicine to evaluate the risk of bias in the included studies. Stata 14.0 software was used for data analysis of the outcome indicators. The outcome indicators of interest in this study were all continuous variables, so the weighted mean difference (WMD) was selected as the effect estimate for analysis, and the 95% confidence interval (CI) corresponding to the effect estimate was calculated. The models for merging the data of each outcome indicator were all random effects models. If there were outcome indicators that involved ≥ 10 included studies, a funnel chart was made to evaluate publication bias.
2.6. Subgroup Analysis
The types of surgery included in this study included TJA and HFS. Based on the above conditions, we conducted subgroup analysis according to different types of surgery (TJA or HFS), which helped us further subdivide the population of POFS patients to obtain more information on clinical value.
3. RESULTS
3.1. Search Results
We initially retrieved 1036 studies. After removing duplicate studies, reading the titles and abstracts, and reading the full texts, 11 RCTs were included in this study [14-24]. The specific retrieval process is shown in Fig. (1).
Fig. (1).
PRISMA flowchart of the selection process.
3.2. Basic Characteristics of the Included Studies
A total of 11 single-center RCTs [17-27] were included in this study. A total of 862 cases were included, including 430 cases in the CHM group and 432 cases in the CG. The sample size included in a single study ranged from 43 to 126 cases. The intervention measures in the CHM group were mainly Chinese herbal formulas and proprietary Chinese medicines, and these herbal medicines were administered mainly to replenish Qi, promote blood circulation, strengthen the spleen, and move Qi. The intervention measures in the CG were routine anti-infective, anticoagulant, and analgesic drugs and rehabilitation exercises. The types of surgery mainly included TJA (TKA or THA) and HFS. The basic characteristics of the included studies are mentioned in Table 1.
Table 1.
Characteristics of 11 included RCTs.
| Study | Intervention | Type of Surgery | Sample Number (Male/Female) | Average Age (Years) | Follow-up | Endpoints | |||
|---|---|---|---|---|---|---|---|---|---|
| CHM | CG | CHM | CG | CHM | CG | ||||
| Liu et al., 2022 [17] | Wufu Jianxi Prescription + CG | RPOT | TKA | 23 (7/16) | 20 (5/15) | 80.3±8.6 | 78.9±8.6 | 3 days | BPOMS, VAS-F |
| Qiu et al., 2021 [18] | Bazhen Decoction + CG | RPOT | THA | 31 (8/23) | 32 (7/25) | 72.84±5.05 | 70.97±6.12 | 7 days | BPOMS, VAS-F, ICFS, IgG |
| Feng et al., 2020 [19] |
Hongjingtian Capsules + CG |
RPOT | THA | 63 (32/31) | 63 (33/30) | 49.92±7.57 | 50.86±9.11 | 3 weeks | BPOMS |
| He Z et al., 2019 [20] | Jianpi Yiqi Huoxue Huayu Prescription + CG | RPOT | TKA | 25 (5/20) | 28 (8/20) | 66.32±8.14 | 67.75±7.7 | 6 days | CHFS |
| Zhou et al., 2019 [21] | Shudi Zhuanggu Prescription + CG | RPOT | THA | 60 (25/35) | 61 (27/34) | 70.68±5.05 | 69.69±5.04 | 2 weeks | CHFS, BPMOS, ICFS, TRF, IgG |
| Yang et al., 2018 [22] |
Hongjingtian Capsules + CG |
RPOT | THA | 57 (30/27) | 57 (28/29) | 44.92±7.90 | 46.81±9.72 | 2 weeks | BPOMS, VAS-F |
| Zheng et al., 2018 [23] | Bazhen Decoction + CG | RPOT | HFS | 28 (11/17) | 28 (13/15) | 79.86±7.89 | 77.57±9.21 | 7 days | BPOMS, VAS-F, ICFS, IgG |
| Zeng et al., 2018 [24] | Buqi Jianpi Huoxue Prescription + CG | RPOT | HFS | 55 (19/36) | 55 (20/35) | 72.35±3.44 | 72.15±3.26 | 7 days | CHFS, TRF |
| Chen et al., 2017 [25] | Taohong Buzhong Yiqi Decoction + CG | RPOT | HFS | 30 (14/16) | 30 (12/18) | 71.23±8.23 | 72.50±7.36 | 7 days | CHFS, TRF |
| Wu et al., 2010 [26] | Jianpi Huoxue Prescription + CG |
RPOT | HFS | 28 (-/-) | 28 (-/-) | NR | NR | 7 days | CHFS |
| He X et al., 2021 [27] |
Yiqi Huoxue Prescription + CG |
RPOT | HFS | 30 (12/18) | 30 (10/20) | 77.57±8.41 | 75.17±9.69 | 6 days | ICFS |
Abbreviations: RCTs: randomized controlled trials; CHM: Chinese herbal medicine; CG: control group; RPOT: Routine Postoperative Treatments; HFS: hip fracture surgery; THA: total hip arthroplasty; TKA: total knee arthroplasty; NR: not reported; CHFS: Christensen fatigue scale; BPOMS: brief profile of mood states; TRF: transferrin; VAS-F: visual analogic scale of fatigue; ICFS: identity-consequence fatigue scale.
3.3. Study Quality Evaluation
In terms of the use of randomization methods, 5 studies [18, 20, 22, 24, 27] used the random number table method, and five studies [17, 19, 22, 23, 25] only mentioned randomization methods but did not specify the specific method. In addition, one study [21] grouped cases according to the order of admission, which was judged as having a high risk of bias. None of the included studies [17-27] described allocation concealment or blinding and were judged as having an unclear risk of bias. The 11 included studies [17-27] had a low risk of bias in terms of incomplete data, selective reporting, and other risks. The overall quality of the included studies was acceptable (Fig. 2).
Fig. (2).
Risk of bias: (A) Quality assessment of individual studies. (B) Each risk of bias item is presented as a percentage across all included studies.
3.4. Meta-Analysis
3.4.1. Primary Outcomes
3.4.1.1. BPOMS
A total of 5 studies [18, 19, 21-23] reported comparative data for the BPOMS. The results of the meta-analysis showed that there was no significant difference between the CHM group and the CG in the comparison of BPOMS scores on the first day after TJA or HFS (WMD=0.08, 95% CI: -0.29 to 0.45, P=0.688). On the 3rd (WMD= -0.85, 95% CI: -1.35 to -0.35, P=0.001) and 7th (WMD= -3.01, 95% CI: -5.86 to -0.16, P=0.039) days after the operation, the BPOMS score of the CHM group was lower than that of the CG (Table 2).
Table 2.
Meta-analysis results of primary outcomes.
| Outcome or Subgroup Title | No. of Studies | No. of Participants | I2 (%) | WMD (95% CI) | p |
|---|---|---|---|---|---|
| BPOMS (POD 1) | 3 | 240 | 0 | 0.08 (-0.29, 0.45) | 0.688 |
| TJA | 2 | 184 | 0 | 0.15 (-0.247, 0.55) | 0.457 |
| HFS | 1 | 56 | NA | -0.39 (-1.38, 0.60) | 0.440 |
| BPOMS (POD 3) | 4 | 283 | 37.5 | -0.85 (-1.35, -0.35) | 0.001 |
| TJA | 3 | 227 | 34.8 | -0.74 (-1.26, -0.22) | 0.006 |
| HFS | 1 | 56 | NA | -1.32 (-2.34, -0.30) | 0.011 |
| BPOMS (POD 7) | 5 | 480 | 97.9 | -3.01 (-5.86, -0.16) | 0.039 |
| TJA | 4 | 424 | 98.5 | -3.31 (-7.10, 0.47) | 0.086 |
| HFS | 1 | 56 | NA | -1.82 (-2.84, -0.80) | <0.001 |
| Christensen (POD 1) | 3 | 234 | 0 | 0.15 (-0.09, 0.39) | 0.214 |
| TJA | 2 | 174 | 0 | 0.13 (-0.13, 0.39) | 0.334 |
| HFS | 1 | 60 | NA | 0.27 (-0.32, 0.86) | 0.372 |
| Christensen (POD 3) | 4 | 290 | 93.8 | -1.01 (-1.94, -0.09) | 0.031 |
| TJA | 2 | 178 | 97.9 | -1.44 (-3.59, 0.71) | 0.188 |
| HFS | 2 | 112 | 0 | -0.59 (-0.97, -0.20) | 0.003 |
| Christensen (POD 7) | 4 | 347 | 93.4 | -1.45 (-2.23, -0.66) | <0.001 |
| TJA | 1 | 121 | NA | -0.39 (-0.71, -0.07) | 0.017 |
| HFS | 3 | 226 | 33.7 | -1.74 (-2.06, -1.42) | <0.001 |
| ICFS (POD 1) | 4 | 300 | 22.4 | -0.40 (-1.84, 1.05) | 0.589 |
| TJA | 2 | 184 | 0 | -0.24 (-1.27, 0.80) | 0.652 |
| HFS | 2 | 116 | 67.9 | -0.96 (-6.86, 4.93) | 0.748 |
| ICFS (POD 3) | 4 | 300 | 84.5 | -3.51 (-6.57, -0.44) | 0.025 |
| TJA | 2 | 184 | 91.1 | -2.92 (-6.73, 0.88) | 0.133 |
| HFS | 2 | 116 | 64.6 | -4.27 (-9.91, 1.38) | 0.139 |
| ICFS (POD 7) | 3 | 240 | 96.6 | -5.26 (-10.33, -0.20) | 0.042 |
| TJA | 2 | 184 | 98.1 | -4.53 (-10.98, 1.93) | 0.170 |
| HFS | 1 | 56 | NA | -6.93 (-10.21, -3.65) | <0.001 |
Abbreviation: WMD: weighted mean difference; POD: postoperative day; HFS: hip fracture surgery; TJA: total joint arthroplasty; CHFS: Christensen fatigue scale; BPOMS: brief profile of mood states; ICFS: identity-consequence fatigue scale; NA: not applicable.
Note: † The forest plots of the primary outcome indicators are shown in Annex 2.
Subgroup analysis by TJA or HFS showed that there was no significant difference in the BPOMS scores of the subgroups on the first day after the operation. On the third day after the operation, the CHM group had lower BPOMS scores for both TJA and HFS patients. In the BPOMS score comparison on the 7th day after the operation, the HFS patients in the CHM group had improved postoperative BPOMS scores, but there was no significant difference for TJA patients compared to the CG (Table 2).
3.4.1.1.1. CHFS
A total of 5 studies [20, 21, 23-26] reported the comparison results of CHFS scores. In the comparison of the CHFS scores on the first day after the operation, there was no significant difference between the CHM group and the CG (WMD=0.15, 95% CI: -0.09 to 0.39, p = 0.214). In the comparison of the CHFS scores on the 3rd day (WMD=-1.01, 95% CI:-1.94 to -0.09, p = 0.031) and the 7th day (WMD=-1.45, 95% CI: -2.23 to -0.66, p <0.001), the CHFS scores in the CHM group were significantly lower than those in the CG (Table 2).
The subgroup analysis results showed that there was no significant difference in the CHFS scores on the first day after the operation in the subgroups. In terms of improved CHFS scores of patients with HFS (the 3rd and 7th postoperative days) and TJA (the 7th postoperative day), the CHM group had better results than the CG (Table 2).
3.4.1.1.2. ICFS
A total of 4 RCTs [18, 21, 23, 27] reported ICFS scores. The results of the meta-analysis showed that there was no significant difference between the two groups in the ICFS scores on the first day after the operation (WMD=-0.40, 95% CI: - 1.84 to 1.05, p = 0.589). In the comparison of ICFS scores between the two groups on the 3rd day (WMD=-3.51, 95% CI:- 6.57 to -0.44, p = 0.025) and the 7th day (WMD = -5.26, 95% CI: - 10.33 to -0.20, p = 0.042) after the operation, the CHM group had lower ICFS scores than the CG, and the difference was statistically significant (Table 2).
The subgroup analysis results showed that there was no significant difference between the two groups on the 1st or 3rd days after the operation. In the comparison of ICFS scores on the 7th day after the operation, the use of CHM for HFS patients showed better efficacy than the use of conventional therapy for patients in the CG, but there was no difference between the two groups among TJA patients (Table 2).
3.5. Secondary Outcomes
3.5.1. TRF
A total of 3 RCTs [21, 24, 25] reported TRF levels. On the 3rd day (WMD=0.51, 95% CI: 0.22 to 0.81, p = 0.001) and 7th day (WMD=0.21, 95% CI: 0.04 to 0.39, p = 0.018) after the operation, the serum TRF concentration of the CHM group was higher than that of the CG, and the difference was statistically significant. There were also significant differences in the subgroup analysis. In the comparison of TRF concentration on the first day after the operation, there was no significant difference in the use of CHM between HFS patients and the CG (Table 3).
Table 3.
Meta-analysis results of secondary outcomes.
| Outcome or Subgroup Title | No. of Studies | No. of Participants | I2 (%) | WMD (95% CI) | P |
|---|---|---|---|---|---|
| TRF (POD 1) | 1 | 60 | NA | -0.30 (-0.81, 0.21) | 0.250 |
| HFS | 1 | 60 | NA | -0.30 (-0.81, 0.21) | 0.250 |
| TRF (POD 3) | 2 | 181 | 17.1 | 0.51 (0.22, 0.81) | 0.001 |
| TJA | 1 | 121 | NA | 0.40 (0.04, 0.76) | 0.030 |
| HFS | 1 | 60 | NA | 0.75 (0.23, 1.28) | 0.005 |
| TRF (POD 7) | 3 | 291 | 97.3 | 0.21 (0.04, 0.39) | 0.018 |
| TJA | 1 | 121 | NA | 0.07 (0.01, 0.13) | 0.016 |
| HFS | 2 | 170 | 94.3 | 0.29 (0.14, 0.43) | <0.001 |
| VAS-F (POD 1) | 2 | 119 | 65.4 | -0.13 (-0.49, 0.23) | 0.474 |
| TJA | 1 | 63 | NA | 0.16 (-0.33, 0.65) | 0.526 |
| HFS | 1 | 56 | NA | -0.47 (-1.00, 0.06) | 0.083 |
| VAS-F (POD 3) | 3 | 162 | 15.3 | -0.64 (-1.00, -0.28) | 0.001 |
| TJA | 2 | 106 | 26.4 | -0.51 (-0.92, -0.10) | 0.015 |
| HFS | 1 | 56 | NA | -0.89 (-1.43, -0.35) | 0.001 |
| VAS-F (POD 7) | 3 | 233 | 97.8 | -1.20 (-2.56, 0.15) | 0.081 |
| TJA | 2 | 177 | 98.7 | -1.44 (-3.23, 0.35) | 0.116 |
| HFS | 1 | 56 | NA | -0.71 (-1.25, -0.17) | 0.011 |
| IgG (POD 1) | 2 | 119 | 45.3 | 0.34 (-0.03, 0.70) | 0.069 |
| TJA | 1 | 63 | NA | 0.11 (-0.39, 0.60) | 0.675 |
| HFS | 1 | 56 | NA | 0.61 (0.07, 1.15) | 0.026 |
| IgG (POD 3) | 3 | 240 | 0 | 0.75 (0.40, 1.10) | <0.001 |
| TJA | 2 | 184 | 0 | 0.62 (0.21, 1.02) | 0.003 |
| HFS | 1 | 56 | NA | 1.13 (0.44, 1.82) | 0.001 |
| IgG (POD 7) | 3 | 240 | 0 | 0.95 (0.59, 1.30) | <0.001 |
| TJA | 2 | 184 | 0 | 0.89 (0.48, 1.31) | <0.001 |
| HFS | 1 | 56 | NA | 1.10 (0.41, 1.79) | 0.002 |
Abbreviation: WMD: weighted mean difference; POD: postoperative day; HFS: hip fracture surgery; TJA: total joint arthroplasty; TRF: transferrin; VAS-F: visual analogic scale of fatigue; NA: not applicable.
Note: † The forest plots of the secondary outcome indicators are shown in Annex 3.
3.5.2. VAS-F
A total of 4 studies [17, 18, 22, 23] reported VAS-F scores. Meta-analysis showed that there was no significant difference between the two groups in VAS-F scores on day 1 (WMD=-0.13, 95% CI: -0.49 to 0.23, p = 0.474) or day 7 (WMD=-1.20, 95% CI:- 2.56 to 0.15, p = 0.081) after the operation. In the comparison on the third day after the operation, the VAS-F score of the CHM group was lower than that of the CG, and the difference was statistically significant (WMD=-0.64, 95% CI: -1.00 to -0.28, p = 0.001) (Table 3).
The subgroup analysis results showed that there was no significant difference in the subgroups on the first day after the operation. In the comparison of VAS-F scores on the 3rd day after the operation, the difference between the two groups was statistically significant in the subgroup analysis. For the VAS-F score comparison on the 7th day after the operation, CHM had better efficacy in HFS patients, but there was no difference in TJA patients (Table 3).
3.5.3. IgG
A total of 3 studies [18, 21, 23] reported the comparison of serum IgG concentrations. The meta-analysis results showed that there was no significant difference between the two groups in the comparison of IgG concentrations on the first day after the operation (WMD= 0.34, 95% CI: -0.03 to 0.70, p = 0.069). In the comparison of IgG concentrations on the 3rd day (WMD=0.75, 95% CI: 0.40 to 1.10, p <0.001) and 7th day (WMD=0.95, 95% CI: 0.59 to 1.30, p <0.001) after the operation, the CHM group had significantly higher serum IgG levels than the CG (Table 3).
Subgroup analysis of CHM administration for TJA and HFS patients showed that IgG levels on the 3rd and 7th days after the operation were significantly different between the two groups (Table 3).
3.6. Publication Bias Evaluation
Since no outcome measures included at least 10 studies, this study did not further develop a funnel chart to evaluate publication bias.
4. DISCUSSION
This study is the first systematic review and meta-analysis of the efficacy of CHM in the treatment of POFS after TJA or HFS and can provide evidence for the treatment of POFS with CHM. This study found that compared to the CG, there was no statistically significant difference in the BPOMS score, CHFS score, or ICFS score in the CHM group on the first day after the operation. The pathogenesis of POFS is complex and has not been fully elucidated. It is generally considered [9, 28] that immune system disorders, neuroendocrine disorders, and metabolic capacity decline occur after the body is injured by surgery, which leads to POFS [29, 30]. We think the best explanation is that trauma after TJA or HFS is very serious and that patients are still under the influence of narcotic drugs; their internal environmental balance, immune system, and stress protection ability are recovering, which may lead to insensitivity to external intervention. This possibility was also reflected in the changes in the secondary outcome indicators, TRF levels, VAS-F scores, and IgG levels. In terms of the improvement in the BPOMS score, CHFS score, and ICFS score on the third and seventh days after surgery, the combined application of CHM based on routine postoperative care significantly improved the fatigue symptoms of patients after TJA or HFS and the three different outcome indicators showed good consistency in the evaluation of the degree of fatigue. Similarly, the application of CHM significantly increased the levels of TRF and IgG in the serum of patients on the 3rd and 7th days after surgery, which plays an important role in enhancing immunity and improving the nutritional status of patients.
Through the analysis of the prescription and drug composition of Chinese patent medicine used in the CHM group, we found that the composition of botanical medicine is considered to invigorate Qi, activate blood circulation, strengthen the spleen, and move Qi in traditional Chinese medicine, which is consistent with the application law of CHM in the treatment of Xulao. Previous studies have found [8, 11, 31, 32] that components of CHM, such as Kaixin San, Danggui Buxue decoction, and Sijunzi decoction, can improve fatigue symptoms by affecting fatigue-related physiological markers, reducing oxidative damage, and enhancing immunity. These plant medicine components that have been proven to be potentially beneficial have the effects of invigorating Qi, activating blood circulation, strengthening the spleen, and moving Qi.
Subgroup analysis was carried out according to the type of surgery, TJA or HFS, and the subgroup analysis results indicated that there was no significant difference between the CHM group and CG in the comparison of the main outcome indicators on the first day after surgery. In addition, we found that in the comparison of different outcome indicators of patients with TJA, the difference between CHM and postoperative routine treatment did not always have the same positive effect, indicating that the use of CHM to treat POFS in TJA patients still shows great inconsistency in terms of different indicators. However, the use of CHM in HFS patients had a positive effect on the improvement of the BPOMS score, CHFS score, VAS-F score, and TRF and IgG levels on the 3rd and 7th days after the operation, indicating that the use of CHM to treat POFS in HFS patients has potential benefits. The conclusions of this study can provide guidance for clinicians in the treatment of POFS in TJA or HFS patients.
This study has the following limitations. First, CHM in this study included different types of herbal formulas and Chinese patent medicines, which may affect the extrapolation of the conclusions of this study. Second, the individuals included in this study were TJA or HFS patients. Although these two types of surgeries are large- and medium-sized bone surgeries, this may have also increased the heterogeneity between studies. Finally, the difference in POFS diagnostic criteria in different included studies may have impaired the reliability of the conclusions of this study. The resolution of the above limitations in future research will be conducive to providing higher-quality evidence-based information.
CONCLUSION
This study found that the use of CHM can improve the degree of fatigue associated with POFS after TJA or HFS and increase the levels of TRF and IgG in serum, which will help clinicians have confidence in using CHM to treat POFS to promote the postoperative rehabilitation process of patients. The subgroup analysis results showed that the use of CHM to intervene in POFS in HFS patients had obvious benefits. Given the objective limitations of this study, future studies need to involve multicenter RCTs on the efficacy of specific types of CHMs to further determine their role in the treatment of POFS.
ACKNOWLEDGEMENTS
Declared none.
LIST OF ABBREVIATIONS
- BPOMS
Brief Profile of Mood States
- CBM
Chinese Biomedical Literature Database
- CG
Control Group
- CI
Confidence Interval
- CNKI
China National Knowledge Infrastructure
- CHFS
Christensen Fatigue scale
- HFS
Hip Fracture Surgery
- ICFS
Identity-Consequence Fatigue Scale
- PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- POFS
Postoperative Fatigue Syndrome
- RCT
Randomized Controlled Trial
- TJA
Total Joint Arthroplasty
- WMD
Weighted Mean Difference
CONSENT FOR PUBLICATION
Not applicable.
STANDARDS OF REPORTING
PRISMA guidelines and methodology were followed.
AVAILABILITY OF DATA AND MATERIALS
The authors declare that the materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes without breaching participant confidentiality.
FUNDING
This study is supported by the Science and Technology Research Project of Guangdong Provincial Hospital of Chinese Medicine, Funder ID: W.Y.Y. Awards/Grant number: No. YN2022GK05, No. YN2019ML08, No. YN2020MS16, the Guangdong Basic and Applied Basic Research Foundation, Funder ID: J.L. Awards/Grant number: No. 2022 A1515010385, No. 2023A1515012626, the Medical Scientific Research Foundation of Guangdong Province, Funder ID: W.Y.Y. Awards/Grant number: No. 20230321102-2372094, and the Project of Guangdong Provincial Department of Finance, Funder ID: J.L. Awards/Grant number: No. (2014)157.
CONFLICT OF INTEREST
The authors declare no conflict of interest, financial or otherwise.
SUPPLEMENTARY MATERIAL
PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.
REFERENCES
- 1.DeCherney A., Bachmann G., Isaacson K., Gall S. Postoperative fatigue negatively impacts the daily lives of patients recovering from hysterectomy. Obstet. Gynecol. 2002;99(1):51–57. doi: 10.1016/S0029-7844(01)01622-2. [DOI] [PubMed] [Google Scholar]
- 2.Lu Y., Yang R., Jiang X., Yang Y., Peng F., Yuan H. Serum metabolite profiles of postoperative fatigue syndrome in rat following partial hepatectomy. J. Clin. Biochem. Nutr. 2016;58(3):210–215. doi: 10.3164/jcbn.15-72. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Zhao L., Zhang H., Cheng H. Effect of a single sub-dose of ketamine on postoperative fatigue syndrome in colorectal cancer patients undergoing radical laparoscopic surgery: A double-blind, pilot study. J. Affect. Disord. 2022;312:146–151. doi: 10.1016/j.jad.2022.06.029. [DOI] [PubMed] [Google Scholar]
- 4.Cui A., Li H., Wang D., Zhong J., Chen Y., Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020;29-30:100587. doi: 10.1016/j.eclinm.2020.100587. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Hamood R., Tirosh M., Fallach N., Chodick G., Eisenberg E., Lubovsky O. Prevalence and incidence of osteoarthritis: A population-based retrospective cohort study. J. Clin. Med. 2021;10(18):4282. doi: 10.3390/jcm10184282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.El Ashmawy A.H., Dowson K., El-Bakoury A., Hosny H.A.H., Yarlagadda R., Keenan J. Effectiveness, patient satisfaction, and cost reduction of virtual joint replacement clinic follow-up of hip and knee arthroplasty. J. Arthroplasty. 2021;36(3):816–822. doi: 10.1016/j.arth.2020.08.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Iglesias B., Jeong H., Bengs B.C., Sanders D.P. SooHoo, N.F.; Buerba, R.A. Total joint replacement surgeon choice: A qualitative analysis in a medicare population. J. Natl. Med. Assoc. 2022;113(6):693–700. doi: 10.1016/j.jnma.2021.08.037. [DOI] [PubMed] [Google Scholar]
- 8.Miao X., Li S., Xiao B., Yang J., Huang R. Metabolomics study of the effect of Danggui Buxue Tang on rats with chronic fatigue syndrome. Biomed. Chromatogr. 2022;36(7):e5379. doi: 10.1002/bmc.5379. [DOI] [PubMed] [Google Scholar]
- 9.Zhuang C.L., Mao X.Y., Liu S., Chen W.Z., Huang D.D., Zhang C.J., Chen B.C., Shen X., Yu Z. Ginsenoside Rb1 improves postoperative fatigue syndrome by reducing skeletal muscle oxidative stress through activation of the PI3K/Akt/Nrf2 pathway in aged rats. Eur. J. Pharmacol. 2014;740:480–487. doi: 10.1016/j.ejphar.2014.06.040. [DOI] [PubMed] [Google Scholar]
- 10.Wang Y.Y., Li X.X., Liu J.P., Luo H., Ma L.X., Alraek T. Traditional Chinese medicine for chronic fatigue syndrome: A systematic review of randomized clinical trials. Complement. Ther. Med. 2014;22(4):826–833. doi: 10.1016/j.ctim.2014.06.004. [DOI] [PubMed] [Google Scholar]
- 11.Cao Y., Hu Y., Liu P., Zhao H.X., Zhou X.J., Wei Y.M. Effects of a Chinese traditional formula Kai Xin San (KXS) on chronic fatigue syndrome mice induced by forced wheel running. J. Ethnopharmacol. 2012;139(1):19–25. doi: 10.1016/j.jep.2011.08.030. [DOI] [PubMed] [Google Scholar]
- 12.Shin S., Park S.J., Hwang M. Effectiveness a herbal medicine (Sipjeondaebo-tang) on adults with chronic fatigue syndrome: A randomized, double-blind, placebo-controlled trial. Integr. Med. Res. 2021;10(2):100664. doi: 10.1016/j.imr.2020.100664. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Page M.J., McKenzie J.E., Bossuyt P.M., Boutron I., Hoffmann T.C., Mulrow C.D., Shamseer L., Tetzlaff J.M., Akl E.A., Brennan S.E., Chou R., Glanville J., Grimshaw J.M., Hróbjartsson A., Lalu M.M., Li T., Loder E.W., Mayo-Wilson E., McDonald S., McGuinness L.A., Stewart L.A., Thomas J., Tricco A.C., Welch V.A., Whiting P., Moher D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int. J. Surg. 2021;88:105906. doi: 10.1016/j.ijsu.2021.105906. [DOI] [PubMed] [Google Scholar]
- 14.Christensen D., Johnsen S.P., Watt T., Harder I., Kirkevold M., Andersen G. Dimensions of post-stroke fatigue: A two-year follow-up study. Cerebrovasc. Dis. 2008;26(2):134–141. doi: 10.1159/000139660. [DOI] [PubMed] [Google Scholar]
- 15.Selmi O., Ouergui I., Muscella A., Levitt D.E., Suzuki K., Bouassida A. Monitoring mood state to improve performance in soccer players: A brief review. Front. Psychol. 2023;14:1095238. doi: 10.3389/fpsyg.2023.1095238. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Li F.L., Li B.C., Huang X., Liu W.H., Huang W.W., Yin D. Different dexamethasone doses in the perioperative period improve short-term outcomes of total hip arthroplasty: A randomized controlled trial. Eur. Rev. Med. Pharmacol. Sci. 2023;27(8):3438–3447. doi: 10.26355/eurrev_202304_32114. [DOI] [PubMed] [Google Scholar]
- 17.Liu L., Shen J., Shen Q., Ling Y., Xie F., Zhang M. Based on the theory of “five viscera and one tonic”, this paper discusses the effect of Wufu jianknee formula on fatigue after knee replacement. Zhejiang J. Trad. Chin. Med. 2022;57(03):191–192. doi: 10.13633/j.cnki.zjtcm.2022.03.005. [DOI] [Google Scholar]
- 18.Qiu Z. Effect observation of Jiawei Bazhen Decoction on improving fatigue syndrome after total hip arthroplasty in the elderly. Guangzhou University of Chinese Medicine; 2021. [DOI] [Google Scholar]
- 19.Feng Y., Qin X. Observation on clinical effects of hongjingtian capsules in relieving postoperative fatigue sydrome after total hip replacement. West. J. Trad. Chin. Med. 2020;33(01):114–118. doi: 10.12174/j.issn.1004-6852.2020.01.30. [DOI] [Google Scholar]
- 20.He Z., He W., Shi Y. Promoting blood circulation and removing blood stasis prescription in the treatment TKA postoperative fatigue syndrome. Clin. J. Trad. Chin. Med. 2019;31(10):1958–1961. doi: 10.16448/j.cjtcm.2019.0568. [DOI] [Google Scholar]
- 21.Zhou J., Gong C., Zhang W. Clinical effect of Pingle Guo’s prescription on fatigue syndrome after total hip arthroplasty in the elderly. Zhongguo Laonianxue Zazhi. 2019;39(17):4221–4225. doi: 10.3969/j.issn.1005-9202.2019.17.036. [DOI] [Google Scholar]
- 22.Yang F., Dan Z., Wang C., Wang J. Clinical study on the treatment of fatigue syndrome after total hip arthroplasty with Hongjingtian capsule in patients with traumatic avascular necrosis of the femoral head. J. Clin. Surg. 2018;26(01):58–61. doi: 10.3969/j.issn.1005-6483.2018.01.018. [DOI] [Google Scholar]
- 23.Zheng W. The clinical observation of modified bazhen decoction in improving postoperative fatigue syndrome of aged intertrochanteric fracture. Fujian University of Traditional Chinese Medicine; 2018. [Google Scholar]
- 24.Zeng W., Kuang Y. The clinical effects of the Buqi Jianpi Huoxue therapy on postoperative fatigue syndrome in elderly patients with hip fracture. Clin. J. Chin. Med. 2018;10(25):69–71. doi: 10.3969/j.issn.1674-7860.2018.25.027. [DOI] [Google Scholar]
- 25.Chen Q., Liu S., Liu Y., Du X. Treatment of 30 cases of fatigue syndrome after hip fracture operation in the elderly by Invigorating Qi, invigorating spleen and activating blood circulation. Chinese J. Trad. Med. Traum. Ortho. 2017;25(08):52–55. [Google Scholar]
- 26.Wu H., Liu W. Observation on the effect of invigorating the spleen and activating blood circulation on fatigue syndrome after hip fracture operation in the elderly. Chinese Community Doctors. 2010;12(16):139. [Google Scholar]
- 27.He X. Clinical study of Yiqi Huoxue recipe in improving perioperative fatigue syndrome of intertrochanteric fracture in the elderly. Guangzhou University of Chinese Medicine; 2021. [DOI] [Google Scholar]
- 28.Mendy N., Moriceau J., Sacuto Y., Besnier E., Clavier T., Ndangang M.M., Castel H., Dureuil B., Compère V. Postoperative fatigue after day surgery: Prevalence and risk factors. A prospective observational study. Minerva Anestesiol. 2020;86(12):1269–1276. doi: 10.23736/S0375-9393.20.14358-X. [DOI] [PubMed] [Google Scholar]
- 29.Nøstdahl T., Bernklev T., Fredheim O.M., Paddison J.S., Raeder J. Defining the cut-off point of clinically significant postoperative fatigue in three common fatigue scales. Qual. Life Res. 2019;28(4):991–1003. doi: 10.1007/s11136-018-2068-0. [DOI] [PubMed] [Google Scholar]
- 30.Nøstdahl T., Bernklev T., Raeder J., Sandvik L., Fredheim O. Postoperative fatigue; translation and validation of a revised 10-item short form of the Identity-Consequence Fatigue Scale (ICFS). J. Psychosom. Res. 2016;84:1–7. doi: 10.1016/j.jpsychores.2016.03.002. [DOI] [PubMed] [Google Scholar]
- 31.Dai L., Zhou W.J., Wang M., Zhou S.G., Ji G. Efficacy and safety of Sijunzi Decoction for chronic fatigue syndrome with spleen deficiency pattern: Study protocol for a randomized, double-blind, placebo-controlled trial. Ann. Transl. Med. 2019;7(20):587–587. doi: 10.21037/atm.2019.09.136. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Yin C., Fu X., Chou J., Li J., Chen Y., Bai J., Wu J., Wu Y., Wang X., Yu Z.L. A proprietary herbal drug Young Yum Pill ameliorates chronic fatigue syndrome in mice. Phytomedicine. 2021;88:153602. doi: 10.1016/j.phymed.2021.153602. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
PRISMA checklist is available as supplementary material on the publisher’s website along with the published article.
Data Availability Statement
The authors declare that the materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes without breaching participant confidentiality.